(Reuters) – Pharmaceutical group GlaxoSmithKline Plc (GSK.L) is said to be in discussions with chipmaker Qualcomm Inc (QCOM.O) to form a joint venture as GSK looks for ways to develop medical technology, Bloomberg reported on Wednesday.
The talks are at an initial stage and nothing has been decided, people familiar with matter told Bloomberg. (bloom.bg/1UbZkSK)
GSK declined to comment, while Qualcomm was not immediately available for comments.
Earlier this month, Qualcomm said it was collaborating with Novartis AG (NOVN.VX) (NVS.N) to develop an inhaler for patients suffering from chronic obstructive pulmonary disease.
(Reporting by Amrutha Penumudi in Bengaluru; Editing by Maju Samuel)
Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.
Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.
Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.